/p>You goa laboratory specializing in generic medicines, has expanded its vademecum in the area of the central nervous system with the launch of the Pramipexole Tevanow available in EFG prolonged release tabletsfor the treatment of the signs and symptoms of idiopathic Parkinson’s disease.
The new EFG prolonged-release tablet formulation allows the administration once a day and goes on the market in three different presentations: 0.26 mg, 1.05 mg and 2.1 mg of 30 tablets each.
Pramipexole Teva It belongs to a group of drugs known as dopamine agonists, is bioequivalent to Mirapexin and is indicated in adults for the treatment of the signs and symptoms of idiopathic Parkinson’s disease, alone or in combination with levodopa.
With this launch, it strengthens its vade mecum in the area of central nervous system in which it already has other generic drugs such as the antidepressants citalopram or mirtazapine, the antiepileptics gabapentin or levetiracetam, the antimigraine drugs rizatriptan or zolmitriptan or the antipsychotic quetiapine, among others.